Published in Cancer Epidemiol Biomarkers Prev on May 07, 2008
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst (2011) 2.27
Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A (2010) 1.71
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Utilization of genomic signatures to identify phenotype-specific drugs. PLoS One (2009) 1.12
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res (2008) 1.08
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther (2009) 1.02
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res (2011) 1.02
Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res (2010) 1.00
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene (2014) 0.95
Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev (2010) 0.93
Quantitative proteomic analysis revealed lovastatin-induced perturbation of cellular pathways in HL-60 cells. J Proteome Res (2011) 0.89
Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes Control (2015) 0.89
Ligand Activation of ERRα by Cholesterol Mediates Statin and Bisphosphonate Effects. Cell Metab (2016) 0.87
Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol (2014) 0.87
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clin Pathol (2015) 0.86
p53 and cancer stem cells: the mevalonate connexion. Cell Cycle (2012) 0.86
Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ERα expression and uterine wet weight in ovariectomized rats. J Bone Miner Metab (2010) 0.86
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. Breast Cancer Res (2011) 0.86
Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer (2016) 0.83
Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis. J Cancer (2016) 0.80
Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. Curr Breast Cancer Rep (2009) 0.79
Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med (2014) 0.78
Plant sterols as anticancer nutrients: evidence for their role in breast cancer. Nutrients (2013) 0.78
Statins, breast cancer, and an invisible switch? Cancer Epidemiol Biomarkers Prev (2008) 0.78
Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis. Lipids Health Dis (2015) 0.77
Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights (2016) 0.75
Statin Use and Breast Cancer Risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev (2016) 0.75
The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. Cancer Prev Res (Phila) (2016) 0.75
Cancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trials. J Geriatr Cardiol (2016) 0.75
Statins and risk of breast cancer recurrence. Breast Cancer (Dove Med Press) (2016) 0.75
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med (2014) 3.78
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res (2009) 3.40
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology (2012) 3.36
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
The UCSC Cancer Genomics Browser. Nat Methods (2009) 3.08
Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 2.83
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2012) 2.49
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg (2012) 2.37
Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med (2007) 2.30
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology (2012) 2.07
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol (2005) 2.06
First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes Control (2014) 2.05
Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol (2002) 2.00
Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol (2002) 1.99
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res (2002) 1.84
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer (2011) 1.77
Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg (2010) 1.70
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol (2008) 1.58
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat (2011) 1.55
Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol (2014) 1.50
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol (2004) 1.45
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J (2006) 1.43
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol (2008) 1.42
Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer (2004) 1.40
Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg (2009) 1.39
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology (2007) 1.38
Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn (2011) 1.37
Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians. J Clin Oncol (2002) 1.37
Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol (2006) 1.34
Socioeconomic status in relation to early menarche among black and white girls. Cancer Causes Control (2008) 1.34
Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res (2004) 1.33
Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer (2008) 1.32
Causes of physician delay in the diagnosis of breast cancer. Arch Intern Med (2002) 1.27
Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A (2006) 1.27
A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A (2009) 1.27
Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol Cell Proteomics (2010) 1.26
Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer (2005) 1.25
ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res (2010) 1.24
Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol (2005) 1.23
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab (2002) 1.21
Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer (2009) 1.20
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res (2011) 1.20
Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res (2004) 1.20
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res (2007) 1.17
Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat (2011) 1.17
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
Optimizing the total skin-sparing mastectomy. Arch Surg (2008) 1.14
Expanding the reach of decision and communication aids in a breast care center: a quality improvement study. Patient Educ Couns (2010) 1.14
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat (2010) 1.14
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res (2012) 1.14
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol (2008) 1.11
Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res (2008) 1.11
Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol Cell Proteomics (2008) 1.11
Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology (2008) 1.10
Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol (2003) 1.10
Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol (2013) 1.10
Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat (2012) 1.10
A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics (2004) 1.10
N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med (2005) 1.08
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1.08
Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler (2010) 1.08
Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc Natl Acad Sci U S A (2010) 1.07
Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol (2007) 1.06